Skip to main content

HubXchange

HubXChange logo

News Xchange

Page Banner 1

Targeting alternative RNA-splicing via NAD⁺ in Alzheimer’s disease

Overview

A new study published in Science Advances (“NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C”) reports that augmentation of the cellular metabolite nicotinamide adenine dinucleotide (NAD⁺) reverses neurological deficits in Alzheimer’s disease (AD) models by correcting widespread alternative splicing errors via the splicing‐regulatory protein EVA1C. 

The work brings together metabolic resilience, RNA‐processing fidelity, and proteostasis in a unified mechanism of neuronal dysfunction and rescue, and has implications for pipeline development in neurodegeneration. This briefing summarises key findings, contextualises them for senior scientists, and outlines translational opportunities and caveats.

Key findings

  • Splicing dysregulation in AD models
    The study demonstrates that dysfunctional alternative splicing events (ASEs) are prominent in ageing and AD brains, and contribute to neuronal vulnerability. 

  • NAD⁺ augmentation rescues ASEs and cognition
    By applying NAD⁺ precursors (eg. nicotinamide riboside / NR, nicotinamide mononucleotide / NMN) in models from worms through mice, the authors show restoration of splicing patterns, gene expression profiles, and behavioural/cognitive readouts. 

  • EVA1C as mechanistic linchpin
    EVA1C levels are reduced in the hippocampus of AD patients vs controls. Knock-down of Eva1c in the hippocampal CA1 region of tauopathy mice abrogates the NAD⁺‐mediated cognitive rescue. Thus, EVA1C is required for the NAD⁺ effect. 

  • Integration of metabolism, splicing and proteostasis.
    The authors used AI and structural modelling to show that specific EVA1C isoforms interact with chaperone systems (eg. HSP70, BAG1), linking NAD⁺ levels to splicing fidelity and downstream protein quality control. 

Implications for the field

  • Mechanistic novelty: This work elevates alternative splicing from a downstream hallmark of neurodegeneration to a mechanistically targetable node — showing that a metabolic intervention (NAD⁺) can recalibrate splicing fidelity via EVA1C.

  • Therapeutic strategy: Given that NAD⁺ precursors are already being investigated in human studies, this research provides a biologic rationale to stratify patients by splicing‐/EVA1C‐related biomarkers, and to test combination strategies (eg. NAD⁺ + splice‐modulating agents).

  • Biomarker maturation: EVA1C expression or splicing‐signature readouts may become early markers of neuronal resilience or early AD vulnerability, enabling earlier intervention in pipeline programmes.

  • Cross‐disease relevance: Splicing abnormalities are increasingly recognised across neurodegenerative conditions (eg. in amyotrophic lateral sclerosis, frontotemporal dementia). This NAD⁺–EVA1C axis may have relevance beyond AD, offering a broader platform for discovery.

Translational considerations & caveats

  • The in-vivo models focus primarily on tauopathy; translation to human AD (mixed Aβ/tau pathology, glial contributions) remains to be established.

  • While NAD⁺ supplementation improved cognition in animal models, the magnitude, timing and durability of effect in humans are unknown; metabolic homeostasis in aged human brains may differ substantially.

  • Splice‐isoform complexity and cell‐type specificity (neurons vs glia) demand careful biomarker design. The authors note limitations regarding isoform‐specific antibodies. 

  • As the commentary acknowledges: this is not a cure — the study is mechanistic and pre‐clinical. Clinical translation will require rigorous design, dosing strategy, endpoint selection (including splicing biomarkers) and safety evaluation of long-term NAD⁺ modulation.

  • Given the multi‐node nature of the mechanism (metabolism → splicing → proteostasis), single‐agent approaches may need to evolve into combinations. Pipeline strategy should consider this.

Strategic take-aways for R&D

  • Early‐stage programmes: Consider incorporating splicing‐signature screens (eg. differential exon usage, ASE burden) in disease models, particularly when testing metabolic or neuronal resilience compounds.

  • Biomarker development: EVA1C expression/splicing, along with splicing‐error load in neuron-enriched fractions, may serve as PD/biomarker endpoints in early-phase trials.

  • Clinical trial planning: For NAD⁺‐related programmes, patient stratification by baseline splicing dysregulation or EVA1C levels may enrich for responders; consider companion diagnostics.

  • Combination strategies: Pairing NAD⁺ precursors with splice‐switching oligonucleotides, small‐molecule splicing modulators or chaperone modulators (HSP70/BAG1 axis) could enhance effect size and durability.

  • Cross-disease extension: Given common splicing dysregulation across neurodegeneration, this axis may be exploitable in other indications (eg. FTD, ALS, Parkinson’s disease) – widening pipeline scope.

Summary

The Science Advances study positions NAD⁺ as a powerful regulator of RNA-splicing fidelity in the aging and Alzheimer’s brain. By restoring NAD⁺, researchers corrected widespread splicing dysregulation through the splicing regulator EVA1C, rebalanced proteostasis signalling networks, and reversed cognitive impairment.

This work highlights a mechanistically compelling and potentially druggable axis uniting metabolism, RNA biology and protein quality control. For senior scientists, the implications are substantial: new biomarkers, new therapeutic targets, and new combinatorial strategies to address neurodegenerative decline at its mechanistic root.

Key Resources

View all News Xchange
Loading
Search